ACR-SNM-SPR practice guideline for the performance of cardiac scintigraphy. ACR practice guideline Oct. 2009. https://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=6414. Accessed 13 Aug 2020.
Akers SR, Werner TJ, Rubello D, Alavi A, Cheng G. 18F-FDG uptake and clearance in patients with compromised renal function. Nucl Med Commun. 2016;37:825–32.
Article
CAS
PubMed
Google Scholar
Aktaş A, Kavak K, Kocabaş B, Aras M, Tütüncü NB, Gençoǧlu A. The biodistribution of radioiodine on posttherapy iodine-131 scans in thyroid cancer patients with chronic renal failure. Nucl Med Commun. 2008;29:943–8.
Article
PubMed
CAS
Google Scholar
Alevizaki C, Molfetas M, Samartzis A, Vlassopoulou B, Vassilopoulos C, Rondogianni P, et al. Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations. Hormones. 2006;5:276–87.
Article
PubMed
Google Scholar
Allisy A. From the curie to the becquerel. Metrologia. 1995;31:467–79.
Article
Google Scholar
Advanced Accelerator Applications. Lutathera - Summary of Product Characteristics (SPC). https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf. Accessed 22 May 2020.
Balon HR, Brown TL, Goldsmith SJ, Silberstein EB, Krenning EP, Lang O, et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39:317–24.
Article
PubMed
Google Scholar
Bartel TB, Kuruva M, Gnanasegaran G, Beheshti M, Cohen EJ, Weissman AF, et al. SNMMI procedure standard for bone scintigraphy 4.0. J Nucl Med Technol. 2018;46:398–404.
PubMed
Google Scholar
Bhat M, Mozzor M, Chugh S, Buddharaju V, Schwarcz M, Valiquette G. Dosing of radioactive iodine in end-stage renal disease patient with thyroid cancer. Endocrinol Diabetes Metab Case Rep. 2017. https://doi.org/10.1530/EDM-17-0111.
Article
PubMed
PubMed Central
Google Scholar
Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008a;35:1934–40.
Article
PubMed
Google Scholar
Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008b;35:1847–56.
Article
CAS
PubMed
Google Scholar
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
Article
CAS
PubMed
Google Scholar
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–8.
Article
PubMed
Google Scholar
Centre for Reviews and Dissemination, University of York. PROSPERO, International prospective register of systematic reviews. https://www.crd.york.ac.uk/prospero/. Accessed 20 May 2019.
Chan P, Croasdale J. Survey of current therapeutic radiopharmaceuticals. In: Theobald T, editor. Sampson’s textbook of radiopharmacy. 4th ed. London: Pharmaceutical Press; 2011. p. 303–23.
Google Scholar
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, et al. Open letter to journal editors. In: International consensus radiochemistry nomenclature guidelines. EJNMMI Radiopharm Chem. 2019.
Courbon F, Hoff M, Caselles O, Duthil P, Zedoud S, Berry I, et al. Iodine-131 treatment of well differenciated thyroid carcinoma in patient on dialysis for chronic renal failure. Eur J Nucl Med. 1997;24:985.
Google Scholar
Courbon F, Caselles O, Zerdoud S, Duthil P, Regis H, Berry I, et al. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications. Q J Nucl Med Mol Imaging. 2006;50:363–70.
CAS
PubMed
Google Scholar
Culpepper RM, Hirsch JI, Fratkin MJ. Clearance of 131I by hemodialysis. Clin Nephrol. 1992;38:110–4.
CAS
PubMed
Google Scholar
Dam HQ, Brandon DC, Grantham VV, Hilson AJ, Howarth DM, Maurer AH, et al. The SNMMI procedure standard/EANM practice guideline for gastrointestinal bleeding scintigraphy 2.0. J Nucl Med Technol. 2014;42:308–17.
Article
PubMed
Google Scholar
Daumerie C, Vynckier S, Caussin J, Jadoul M, Squifflet JP, de Patoul N, et al. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Thyroid. 1996;6:301–4.
Article
CAS
PubMed
Google Scholar
Demko TM, Tulchinsky M, Miller KL, Cheung JY, Groff JA. Diagnosis and radioablation treatment of toxic multinodular goiter in a hemodialysis patient. Am J Kidney Dis. 1998;31:698–700.
Article
CAS
PubMed
Google Scholar
Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53:154–63.
Article
CAS
PubMed
Google Scholar
Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4:1065–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Driedger AA, Quirk S, McDonald TJ, Ledger S, Gray D, Wall W, et al. A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure. Clin Nucl Med. 2006;31:454–7.
Article
CAS
PubMed
Google Scholar
El-Zeftawy HA, Zekri JM, Farag K, Al-Saadi R, Sadiq BMB, Miliebari S. Radioiodine I-131 ablation therapy and impaired renal function: possible impact on guidelines. J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.e17591.
Article
Google Scholar
European Medicines Agency: Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. London, European Medicines Agency, 2015. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf. Accessed 28 May 2020.
Fahey F, Stabin M. Dose optimization in nuclear medicine. Semin Nucl Med. 2014;44:193–201.
Article
PubMed
Google Scholar
Fofi C, Festuccia F, Barberi S, Apponi F, Chiacchiararelli L, Scopinaro F, et al. Hemodialysis in patients requiring 131I treatment for thyroid carcinoma. Int J Artif Organs. 2013;36:439–43.
Article
CAS
PubMed
Google Scholar
GE Healthcare BV. Theracap 131: summary of product characteristics (SPC). https://www.geneesmiddeleninformatiebank.nl/smpc/h57765_smpc.pdf. Accessed 14 Aug 2020.
Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A. The prevalence of renal failure. Results from the German health interview and examination survey for adults, 2008–2011 (DEGS1). Dtsch Arztebl Int. 2016;113:85–91.
PubMed
PubMed Central
Google Scholar
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0158765.
Article
PubMed
PubMed Central
CAS
Google Scholar
Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005;15:1321–31.
Article
CAS
PubMed
Google Scholar
Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with (177)Lu-DOTATATE. J Nucl Med. 2019;60:937–43.
Article
CAS
PubMed
Google Scholar
Howard N, Glasser M. Iodine 131 ablation therapy for a patient on maintenance haemodialysis. Br J Radiol. 1981;54:259–1285.
Article
CAS
PubMed
Google Scholar
International Society of Nephrology. Chapter 1: Definition and classification of CKD. Kidney international supplements. 2013; 3:19–62. https://doi.org/10.1038/kisup.2012.64.
Jiménez RG, Moreno AS, Gonzalez EN, Simón FJL, Rodriguez JR, Jimenez JC, et al. Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method. Thyroid. 2001;11:1031–4.
Article
PubMed
Google Scholar
Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab. 2000;85:3058–64.
CAS
PubMed
Google Scholar
Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46(Suppl 1):4S-12S.
PubMed
Google Scholar
Kode V, Karsch H, Osman MM, Muzaffar R. Impact of Renal Failure on F18-FDG PET/CT Scans. Front Oncol. 2017;7:155.
Article
PubMed
PubMed Central
Google Scholar
Konijnenberg M, Herrmann K, Kobe C, Verburg F, Hindorf C, Hustinx R, Lassmann M. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021;48(1):67–72. https://doi.org/10.1007/s00259-020-05038-9.
Article
PubMed
Google Scholar
Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20:e200–7.
Article
CAS
PubMed
Google Scholar
Laffon E, Cazeau AL, Monet A, de Clermont H, Fernandez P, Marthan R, et al. The effect of renal failure on 18F-FDG uptake: a theoretic assessment. J Nucl Med Technol. 2008;36:200–2.
Article
PubMed
Google Scholar
Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. J Nucl Med. 2019;60(Suppl 2):13S-19S.
Article
CAS
PubMed
Google Scholar
Lassmann M, Treves ST. EANM/SNMMI Paediatric Dosage Harmonization Working Group. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging. 2014;41:1036–41.
Article
CAS
PubMed
Google Scholar
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.
Article
CAS
PubMed
Google Scholar
Magné N, Magné J, Bracco J, Bussière F. Disposition of radioiodine (131)I therapy for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis: a case report. Jpn J Clin Oncol. 2002;32:202–5.
Article
PubMed
Google Scholar
Matzke GR, Frye RF. Drug administration in patients with renal insufficiency: minimising renal and extrarenal toxicity. Drug Saf. 1997;16:205–31.
Article
CAS
PubMed
Google Scholar
McKay E, Malaroda A. Predicting the biodistribution of radioiodide in the setting of renal impairment and dialysis. Intern Med J. 2019;49:22.
Google Scholar
McKillop JH, Leung AC, Wilson R. Successful management of Graves’ disease in a patient undergoing regular dialysis therapy. Arch Intern Med. 1985;145:337–9.
Article
CAS
PubMed
Google Scholar
Meller J, Sahlmann CO, Becker W. Nuclear medicine studies in the dialysis patient. Semin Dial. 2002;15:269–76.
Article
PubMed
Google Scholar
Mello AM, Isaacs R, Petersen J, Kronenberger S, McDougall IR. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Clin Nucl Med. 1994;19:776–81.
Article
CAS
PubMed
Google Scholar
Meredith R, Wessels B. Knox S. Risks to normal tissues from radionuclide therapy. Semin Nucl Med. 2008;38:347–57.
Article
PubMed
Google Scholar
Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues. Ann Nucl Med. 2007;21:217–22.
Article
CAS
PubMed
Google Scholar
Miyasaka Y, Yoshimura M, Tabata S, Shozu A, Nishikawa M, Iwasaka T, et al. Successful treatment of a patient with Graves’ disease on hemodialysis complicated by antithyroid drug-induced granulocytopenia and angina pectoris. Thyroid. 1997;7:621–4.
Article
CAS
PubMed
Google Scholar
Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097.
Article
PubMed
PubMed Central
Google Scholar
Morrish DW, Filipow LJ, McEwan AJ, Schmidt R, Murland KR, von Westarp C, et al. 131I treatment of thyroid papillary carcinoma in a patient with renal failure. Cancer. 1990;66:2509–13.
Article
CAS
PubMed
Google Scholar
Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Phys. 2007;75:1487–96.
Google Scholar
National Kidney Foundation, Inc. Kidney Disease. How to Classify CKD. https://www.kidney.org/professionals/explore-your-knowledge/how-to-classify-ckd. Accessed 5 Jun 2019.
Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis. 2001;37:1177–83.
Article
CAS
PubMed
Google Scholar
Ottawa Hospital Research Institute. Newcastle-Ottawa Scale. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 5 Jun 2019.
Pahlka RB, Sonnad JR. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients—a pharmacokinetic model. Health Phys. 2006;91:227–37.
Article
CAS
PubMed
Google Scholar
Pickett R. Radiopharmacokinetics. In: Theobald T, editor. Sampson’s textbook of radiopharmacy. 4th ed. London: Pharmaceutical Press; 2011. p. 219–47.
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:824–45.
Article
CAS
PubMed
Google Scholar
Saracyn M, Bilski M, Kaminski G, Niemczyk S. Can radioiodine be administered effectively and safely to a patient with severe chronic kidney disease? Clin Endocrinol (oxf). 2014;81:169–74.
Article
CAS
Google Scholar
Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53:1633–51.
Article
PubMed
Google Scholar
Silberstein EB, Buscombe JR, McEwans A, Taylor AT. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases. In: Society of nuclear medicine procedure guidelines manual. 2003. p. 145–153.
Singh M, Kaur J, Singh S, Thumburu K, Jaiswal N et al. Comparison of Newcastle Ottawa scale (NOS) and Agency for Health Research and Quality (AHRQ) as risk of bias assessment tools for cohort studies. Filtering the information overload for better decisions. Abstracts of the 23rd Cochrane Colloquium. . John Wiley and Sons, Vienna, Austria. 2015.
Sinsakul M, Ali A. Radioactive 131I use in end-stage renal disease: nightmare or nuisance? Semin Dial. 2004;17:53–6.
PubMed
Google Scholar
Sjögreen Gleisner K, Spezi E, Solny P, Gabina PM, Cicone F, Stokke C, et al. Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Phys. 2017;4:28.
Article
PubMed
PubMed Central
Google Scholar
Smith BT. Radioactive drugs in medicine: radiopharmaceuticals. In: Smith BT, Weatherman KD, editors. Diagnostic imaging for pharmacists. 1st ed. Washington, DC: American Pharmacists Association; 2012. p. 2–8.
Google Scholar
Stokke C, Gabiña PM, Solný P, Cicone F, Sandström M, Gleisner KS, Chiesa C, Spezi E, Paphiti M, Konijnenberg M, Aldridge M, Tipping J, Wissmeyer M, Brans B, Bacher K, Kobe C, Flux G. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. EJNMMI Phys. 2017;4(1):27. https://doi.org/10.1186/s40658-017-0194-3.
Article
PubMed
PubMed Central
Google Scholar
Svensson J, Hermann R, Larsson M, Forssell-Aronsson E, Wängberg B, Ahlman H, et al. Impairment in renal function predicts higher absorbed doses to the kidneys in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:S307.
Google Scholar
Tobes MC, Fig LM, Carey J, Geatti O, Sisson JC, Shapiro B. Alterations of iodine-131 MIBG biodistribution in an anephric patient: Comparison to normal and impaired renal function. J Nucl Med. 1989;30:1476–82.
CAS
PubMed
Google Scholar
Toriihara A, Kitazume Y, Nishida H, Kubota K, Nakadate M, Tateishi U. Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls. Am J Nucl Med Mol Imaging. 2015;5:204–11.
PubMed
PubMed Central
Google Scholar
Toubert ME, Michel C, Metivier F, Peker MC, Rain JD. Iodine-131 ablation therapy for a patient receiving peritoneal dialysis. Clin Nucl Med. 2001;26:302–5.
Article
CAS
PubMed
Google Scholar
Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43:1723–38.
Article
PubMed
PubMed Central
Google Scholar
Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol. 2014;10:1131–43.
Article
CAS
PubMed
Google Scholar
Vermandel M, Debruyne P, Beron A, Devos L, Talbot A, Legrand JF, et al. Management of patients with renal failure undergoing dialysis during (131)I therapy for thyroid cancer. J Nucl Med. 2020;61:1161–70.
Article
CAS
PubMed
Google Scholar
Wang TH, Lee CH, Tseng LM, Liu RH. The management of well-differentiated thyroid cancer with end-stage renal disease. Endocrine. 2003;21:227–31.
Article
PubMed
Google Scholar
Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, et al. Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis. Drug Saf. 2018;41:603–13.
Article
PubMed
PubMed Central
Google Scholar
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2019. https://www.whocc.no/atc_ddd_index/. Accessed 14 Jun 2019.
Willegaignon J, Ribeiro VP, Sapienza M, Ono C, Watanabe T, Buchpiguel C. Is it necessary to reduce the radioiodine dose in patients with thyroid cancer and renal failure? Arq Bras Endocrinol Metabol. 2010;54:413–8.
Article
PubMed
Google Scholar
Yeyin N, Cavdar I, Uslu L, Abuqbeitah M, Demir M. Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure. Nucl Med Commun. 2016;37:283–7.
Article
CAS
PubMed
Google Scholar
Zaknun JJ, Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.
Article
CAS
PubMed
PubMed Central
Google Scholar